Lih-Ling Lin, PhD, is a Senior Director, currently leading the Exploratory Innate Immunity group, focusing on the emerging science for the drug discovery effort in the Inflammation & Immunology Research Unit.  Dr. Lin received her undergraduate degree in Pharmacy from National Taiwan University in Taipei, Taiwan and a PhD degree in Biochemistry from the University of Arizona. Dr. Lin joined legacy Wyeth (formerly Genetics Institute) and contributed to the discovery of several key phospholipases that are important in inflammatory response. She has led a discovery team targeting the innate immunity signal transduction pathways involved in the production of inflammatory mediators contributing to the pathogenesis of diseases. These projects include developments of small molecule kinase inhibitors and biologics targeting innate receptors and cytokines, leading to the discovery of clinical candidates in treating autoimmune and inflammatory diseases, such as rheumatoid arthritis. Dr. Lin is an author of over 70 scientific papers and patents.

drug discovery,Biochemistry,Genetics